Marginum raised €2.5 million in Pre-Series A funding to advance its HIVEN® device for brain tumor detection and facilitate FDA approval.

Target Company Overview

Marginum, a health technology startup, has successfully raised €2.5 million in a Pre-Series A funding round to secure FDA approval for its innovative HIVEN® device and to accelerate its international launch. This advanced device employs optical tissue monitoring technology to facilitate the safe and effective detection of brain tumors during surgical procedures.

The HIVEN® device enhances surgical precision by allowing surgeons to verify whether the excised tissue contains cancerous cells or healthy tissue during surgery. The device's capability to reduce the need for secondary surgeries significantly improves patient outcomes. By utilizing fluorescence-based technology, patients receive a fluorescent agent before surgery that causes cancer cells to glow red, enhancing detection during operations.

Industry Overview in Finland

Finland's healthcare industry is experiencing a transformative period, driven by advancements in medical technology and a strong commitment to innovative healthcare solutions. The country is recognized for its robust healthcare system and high